Understand the 340B Program and how the changes can affect multiple healthcare organizations.
The past few years have been an unusually tumultuous time in the 340B Program. This topic will outline the main challenges and opportunities for 340B Program stakeholders. The presenters will underline the practical steps that 340B Program stakeholders can take to ensure compliance and optimize 340B Program participation during the current shifting state of the 340B Program.
Learning Objectives
- You will be able to review 340B background.
- You will be able to identify recent program changes.
- You will be able to discuss legislative updates.
- You will be able to recognize compliance problem areas and best practice strategies.
Agenda
340B Program Background
- General Refresher on the 340B Program and Program History
- A High-Level Overview of Main 340B Program Requirements and Regulations
- Eligible Patient Definition Discussion
Recent Program Updates (Litigation)
- Update on the Current State of Manufacturer Restrictions and Appellate Court Review of Ongoing Litigation
- Update on Genesis Case and Impact on Eligible Patient Definition
- Potential Impact on Loper Supreme Court Case on 340B Program
Recent Program Updates (Legislative)
- Update on State-Level Contract Pharmacy Protection Laws
- Update on State-Level Pbm 340B Anti-Discrimination Laws
- Update on State and Federal 340B Transparency Initiatives
340B Optimization Strategies
- Alternative Distribution Models for Contract Pharmacy Arrangements
- Medication Therapy Management Clinics
- Referral Prescription Capture
Speakers
Mr Michael French, J.D.,
Quarles & Brady LLP- Associate at Quarles & Brady LLP
- Assists with successfully navigating 340B HRSA audits, including data request submissions, support during the on-site portion of an audit, and drafting corrective action plans and/or Notice of Disagreements to mitigate the impact of findings
- Conducts client-facing 340B pharmacy operational assessments to assess compliance and identify opportunities to maximize available 340B savings
- Provides advice and counsel on strategies for avoiding 340B diversion and Medicaid duplicate discounts, including best practices for meeting associated federal and State-level billing requirements
- Drafts 340B contract pharmacy services agreements to maintain compliance with associated 340B regulations and ensure operational efficiencies for all parties involved
- Assists covered entities and contract pharmacies with Third-Party Administrator (TPA) implementation, best strategies for configuration set-up, and maintenance of software settings to ensure compliance
- J.D. degree, magna cum laude, Loyola University Chicago School of Law; B.A. degree, University of Notre Dame
Mr Richard Davis, J.D.,
Quarles & Brady LLP- Associate at Quarles & Brady LLP
- Assists in implementing and enhancing 340B drug pricing programs across a wide variety of health systems, enabling the health systems to obtain millions of dollars in savings
- Provides ongoing compliance and operational support to 340B participating entities
- Successfully disputes and mitigates HRSA OPA audit findings, enabling these entities to retain their 340B savings in addition to contracting with various national retail pharmacy chains and 340B program software vendors
- Drafts memoranda interpreting and analyzing HRSA OPA 340B program guidance based on relevant Medicare and Medicaid statutory and regulatory language
- Assists covered entities and contract pharmacies in navigating recent manufacturer disputes
- J.D. degree, with honors, University of Wisconsin Law School; B.A. degree in international affairs, George Washington University
Who Should Attend
This live webinar is designed for medical records directors, health information managers, facility administrators, billing managers, compliance officers, coders, and attorneys.
